KRAS P.G12C

Clinical trials for KRAS P.G12C explained in plain language.

Never miss a new study

Get alerted when new KRAS P.G12C trials appear

Sign up with your email to follow new studies for KRAS P.G12C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Not yet finished but already full! 2

New pill targets 'Undruggable' cancer mutation in major trial

Disease control Recruiting now

This early-stage trial is testing a new oral medication called D3S-001 for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The main goals are to find a safe dose, see how the body processes the drug, and get early signs of whether it helps …

Matched conditions: KRAS P.G12C

Phase: PHASE1, PHASE2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control

Last updated Mar 30, 2026 14:28 UTC

KRAS P.G12C

Get alerted when new KRAS P.G12C trials appear

New pill targets 'Undruggable' cancer mutation in major trial